Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment — Albert Oriol (2023) | RDL Network
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.
Albert Oriol, Meletios A Dimopoulos, Fredrik Schjesvold, M. Beksac, Münci Yağcı, Alessandra Larocca, S. Guo, Y. Mu, Kevin Hong, Sujith Dhanasiri, PG Richardson, Katja Weisel
Albert Oriol Rocafiguera, Meletios A Dimopoulos, Fredrik Schjesvold, Meral Beksaç, Münci Yağcı, Alessandra Larocca, Shien Guo, Yutian Mu, Kevin Hong, Sujith Dhanasiri, Paul G. Richardson, Katja Weisel
Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, J. Dürig, Michel Pavic, Morten Salomo, Xiaoyong Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mounir Zaki, Paul G. Richardson
Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Eva Casal, Shankar Srinivasan, Xin Yu, Tuong Vi Nguyen, Tsvetan Biyukov, Teresa Peluso, Paul G. Richardson
Holger W. Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Špıčka, Luděk Pour, Meletios A Dimopoulos, Iryna Kriachok, Halyna Pylypenko, Xavier Leleu, Vadim Doronin, Ganna Usenko, Roman Hájek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau,
Discussion(0)
No comments yet. Be the first to comment.